

A Revitalising Approach towards Aging: Unveiling the Potential Use of Probiotics for Wellness in Elderly Populations

Shanaya Phal Desai, B.Sc., Christine Kurian, M.Sc., Semanti Das, B.Sc.,
Stena Jesima Rebello, B.Sc., Sayanti Acharyya, B.Sc., Kuppusamy Alagesan Paari, Ph.D.

Department of Life Sciences, CHRIST (Deemed to be University), Bangalore, Karnataka 560029, India.

Received 26 July 2023 • Revised 11 September 2023 • Accepted 19 September 2023 • Published online 12 December 2023

Abstract:

Probiotics have emerged as a potential alternative for treating various diseases affecting general population. Mounting data suggests that probiotics can be beneficial for older individuals, who often have weakened immune systems and are more susceptible to illnesses. Dysbiosis commonly occurs in elderly individuals, which is implicated as a major reason for various diseases. The effectiveness of probiotics is influenced by the specific strain and the dosage administered. Extensive studies have shown how probiotics affect prevalent issues, such as functional bowel diseases and other gastrointestinal disorders. Probiotics exert their effects by synthesizing different microbial peptides, such as bacteriocins, antibiotics, lipopolysaccharides, short-chain fatty acids, butyric acid, propionic acid and other specific secretory metabolites. The common probiotics that are found to benefit the health of elderly populations include *Lactobacillus*, *Bifidobacterium lactis*, *Bacillus subtilis*, *Bifidobacterium longum* and *Bifidobacterium breve*. Further research is necessary to delve into the mechanism of action for both existing and novel probiotic strains for use in combating or aiding in diseases. Genetically, modified probiotics can be potentially used in the future to deliver immunity-restoring genes and as oral mode of vaccination in humans. Fecal microbiota transplantation has been gaining interest, used to restore gut conditions, and has also been linked to alleviating neurodegenerative diseases. The focus of this review was to present the available evidence on the immunomodulatory effects of probiotics in the elderly population; aiming to gain a better understanding of their mechanism of action and to assess the progress made in utilizing probiotics as therapeutic interventions.

Keywords: bacteriocins, disease management, dysbiosis, gut homeostasis, immunomodulatory, immunosenescence, microbiota therapy, probiotics

Contact: Kuppusamy Alagesan Paari, Ph.D.
Department of Life Sciences, CHRIST (Deemed to be University), Bangalore,
Karnataka 560029, India.
E-mail: paari.ka@christuniversity.in

J Health Sci Med Res
doi: 10.31584/jhsmr.20231015
www.jhsmr.org

© 2023 JHSMR. Hosted by Prince of Songkla University. All rights reserved.
This is an open access article under the CC BY-NC-ND license
(<http://www.jhsmr.org/index.php/jhsmr/about/editorialPolicies#openAccessPolicy>).

Introduction

Probiotics are living microorganisms that, when appropriately administered, can confer health benefits to the host¹. Probiotics are administered in the form of capsules, tablets, powder, drinks and fermented foods, such as yogurt². For a strain of bacteria to be called a probiotic, it has to confer specific properties, such as resistance to gastric acid and bile acids, bile salt hydrolase activity, ability to adhere to mucus or epithelial cells, exhibit antimicrobial properties and potentially reduce the infection of pathogenic bacteria in the gut³. No specific mode of action is clearly understood; however, probiotics are known to exhibit competitive exclusion by reducing the luminal pH and competing for nutrition and resources, majorly by producing bacteriocins or specific metabolites⁴. The commonly used probiotics include: Lactobacilli, such as *Lactobacillus acidophilus*, *L. paracasei*, *L. casei*, *L. rhamnosus*, *L. plantarum*, *L. delbrueckii* subsp. *bulgaricus*, *L. brevis*, *L. johnsonii*; and *Bifidobacterium* such as *Bifidobacterium infantis*, *B. breve*, *B. adolescentis*, *B. animalis* subsp *animalis*, *B. animalis* subsp *lactis*, *B. bifidum* and *B. longum*³.

Various species of Lactic acid bacteria (LAB), such as *Lactobacillus*, *Lactococcus*, *Bifidobacterium* and *Leuconostoc*, are prominent exopolysaccharide (EPS) producing probiotics⁵. The health benefit of LAB can be conferred to its production of EPS that are claimed to have immunostimulatory activity, antitumor potential and cardiovascular effects⁶. Probiotic EPS can be supplemented in diseases, such as inflammatory bowel diseases, autoimmune diseases, gastric ulcers and cardiovascular disease, as they have the ability to survive in the antagonistic conditions of the gut and also act against antibiotics, which suppresses the immune responses and affects the gut microflora if ingested regularly⁵.

Aging is the functional deterioration of the body due to a multifactorial process that occurs in the body caused by DNA damage, resulting in immunological alterations⁷. As individuals age the bacterial metabolites produced are

also are altered, such as short-chain fatty acids (SCFA), acetate, butyrate, lactate and succinate. SCFAs play a major role in preventing gastrointestinal diseases, such as metabolic syndromes and bowel disorders.

Antibiotic resistance is a leading global problem in medicine and cures. Antibiotic resistance has led to many problems, such as antibiotic-associated diarrhea and gut dysbiosis, which leads to an imbalance in the microflora. *Lactobacillus*, a gram-positive bacteria, has a wide range of applications as a probiotic. Previously, different strains of *Lactobacillus* have been observed to have deliberate, beneficial effects like inhibition of pathogenic bacteria, such as *Helicobacter* and *Salmonella*, alleviation of gastrointestinal inflammation, antibiotic-associated diarrhea and boosting of the immune system, *L. paracasei* has also been observed to have potential anti-colon cancer properties⁸⁻⁹. Probiotics produce specific metabolites, such as conjugated linoleic acids, which are proven to prevent the differentiation of cancer cells¹⁰. Metabolites, like butyrate in colon cancer cells, were found to inhibit cell growth and differentiation through their action on the inhibition of histone deacetylases¹¹.

Different probiotic strains can treat divergent diseases based on their mode, mechanism of action and dosage. *Bifidobacterium* and *Faecalibacterium prausnitzii* both exhibit anti-inflammatory responses and are seen in lower numbers in diabetic individuals¹²⁻¹³. Probiotics *Lactobacillus casei*, *Lactobacillus acidophilus* has been observed to lower blood glucose level and alleviates diabetes-related symptoms, such as dyslipidemia, glucose tolerance, hyperglycemia and oxidative stress in trials on rats¹⁴⁻¹⁵. Probiotics potentially modulate the toll-like receptors (TLR) and proteoglycan recognition proteins in enterocytes leading to activation of Th1 responses, which can suppress Th2 responses in allergic disorders. Allergies are associated to a shift in Th1/Th2 cytokine towards a Th2 response causing the release of interleukin-4, interleukin-5, interleukin-13 and IgE production involved in

allergic reactions¹⁶⁻¹⁷. *L. plantarum* was shown to increase IL-10 concentration, indicating the anti-inflammatory effects, ameliorate inappropriate inflammation and induce tolerance¹⁸. Additionally, the *Bacteroides fragilis* strain ZY-312 has been previously found to be beneficial in antibiotic-associated diarrhoea (AAD) in mouse model studies through epithelial cell proliferation and differentiation¹⁹.

As individuals age, there is a decline in liver volume and blood flow as well as which liver regeneration is slower. The liver has an indirect connection with gut microbiota. When the liver is under stressed conditions, due to various diseases, the intestinal microbiota undergo dysbiosis, which accelerates the liver fibrosis and cirrhosis process by increasing inflammatory responses. Animal model-based studies have suggested that aging leads to a decline in the drug-metabolizing ability of the liver, decreased microsomal content of cytochrome p-450 and decreased alcohol dehydrogenase activity²⁰⁻²². Non-alcoholic fatty liver disease is predominantly a disease affecting the middle aged to older people, and is characterized with excess fat deposition in the liver, advanced fibrosis and can also lead to hepatocellular cancer²³. Studies have shown that some strains of probiotics can improve liver conditions by bringing about changes in the gut, via decreasing the production of endotoxins and toxic substances, such as ethanol, phenol, and indoles, which have the tendency to damage the liver. They help downregulate NF- κ B and reduce the production of pro-inflammatory factors, such as TNF- α , IL-6 and IFN- γ . Commonly targeted probiotics include *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Lactobacillus casei*, *Lactobacillus bulgaricus*, *Bifidobacterium* *berve*, *Bifidobacterium longum* and *Bifidobacterium infantis*; however, most of the experiments have been conducted on animal models and the data on human clinical trials is insufficient²⁴.

Probiotics regulate host bile salt metabolism through a series of enzymatic reactions and exhibit bile

salt hydrolase activity. Any disruption in bile salt pools can lead to dysbiosis, which is common in elderly populations. The microbiota express, farnesoid X receptor (FXR), a bile acid-activated regulatory element and G-protein-coupled bile acid receptor (TGR5), and any imbalance in the gut can affect the probability of acquiring liver²⁵. The Probiotic strains *Bifidobacterium* and *Lactobacillus* bacteria have shown bile salt deconjugation activity and high bile salt hydrolase (BSH) activity²⁶. Several probiotic strains have a cholesterol-lowering activity, such as *Lactobacillus acidophilus*, *L. bulgaricus* FTCC 0411, *L. reuteri* NCIMB 30242 and *L. delbrueckii* *ssp. bulgaricus* A13²⁷⁻³¹.

Certain strains of probiotics, which confer beneficial effects, can also be pathogenic to a few. Studies have found that *Bacteroides* can cause endotoxicity in host individuals with diabetes or surgical patients, as these strains have lipopolysaccharides that can activate TLR-2 and TLR-4 signaling³². Probiotics can also be used as adjuvants to antibiotic therapies to increase the effectiveness of the treatment. Previously Beausoleil et al, employed 50x10⁹ CFU units of *L. acidophilus* CL1285 and *L. casei* on elderly patients with gastrointestinal disorders and found that the response to treatment in the probiotic-administered group was better than the placebo group. This review summarizes the various findings and evidence about probiotics' use and potential therapeutic applications on the elderly and older populations³³.

Sources and secretory metabolites of probiotics

Different strains of the same probiotic can have different effects on the human body, and a single dose cannot be generalized to be effective for all strains³⁴. The common source of probiotic isolation is dairy, and dairy-related products, such as *Lactobacillus* and *Bifidobacteria*, which are obtained from fermented milk. The probiotic bacterial strain *L. plantarum* was previously isolated from Italian, Argentinean, and Bulgarian cheeses³⁵. Human

breast milk has also been recognized as a rich source of probiotics, such as *Bifidobacterium breve*, *Bifidobacterium bifidum*, *Bifidobacterium adolescentis*, *Lactobacillus gasseri*, *Lactobacillus fermentum*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, and *Lactobacillus salivarius*, which confers to infant's enhanced development, increased immunity and a healthy gut³⁶. In an experiment, Li et al, isolated probiotic *B. velezensis* from the faeces of healthy domestic yak, *L. plantarum* from beef cattle faeces and *L. salivarius* from swine to test its performance in improvement of intestinal health in mice³⁷. Fermented food products are also sources for the isolation of several probiotics, such as Kimchi (Korean dish) containing several vegetable mixtures, and fermented olives have been used to isolate *L. brevis*, *L. plantarum*; *L. brevis*, and *L. Lactis* from Bamboo shoots; and *L. rhamnosus* from fermented cabbage³⁸. The animal gut also harbors several naturally beneficial probiotics, which can be isolated from the faeces of the organism. Handajani et al, isolated *Limosilactobacillus fermentum* from tempeh, a

traditional Indonesian food made of fermented soyabeans, to study the effect of probiotics on an elderly population with cognitive impairment³⁹ (Table 1).

The diverse synthesis of antimicrobial peptides by probiotics called: bacteriocins, helps it compete with the gut pathogens and also modulates the insensitive bacterial species in the Gastrointestinal (GI) tract⁴⁰. Bacteriocins can impart immunity by releasing cell lysing compounds that cause viral lysis, Lantibiotics, which are class I bacteriocins, inhibit bacterial cell wall biosynthesis by binding to carrier molecules of peptidoglycan monomers required for building the cell wall; called the Lipid II, and also use this lipid molecule as a docking molecule to initiate pore formation in the bacterial membrane. Certain bacteriocins (class IIc) can directly interact with the bacterial membrane without any receptor molecules⁴¹.

Microbes colonize the body soon after birth and act to strengthen the gut epithelium. The imbalance in gut microbes, due to several factors in aged individuals,

Table 1 Different sources of isolation of probiotics strains

Source	Probiotic strains	References
Milk	<i>Lactobacillus</i>	39
Breast milk	<i>Bifidobacterium breve</i> , <i>Bifidobacterium bifidum</i> , <i>Bifidobacterium adolescentis</i> , <i>Lactobacillus gasseri</i> , <i>Lactobacillus fermentum</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus rhamnosus</i> , and <i>Lactobacillus salivarius</i>	
Cheese	<i>L. plantarum</i>	42
Butter milk	<i>Lactococcus lactis</i> , <i>Lactobacillus bulgaricus</i>	52-53
Whey beverage	<i>Bifidobacterium lactis</i> , <i>Lactobacillus acidophilus</i>	52-54
Kimchi, olives (fermented food)	<i>L. brevis</i> , <i>L. plantarum</i> ; <i>L. brevis</i> ,	43
Bamboo shoots	<i>L. Lactis</i>	39
Fermented cabbage	<i>L. rhamnosus</i>	42
Tempeh	<i>Limosilactobacillus fermentum</i>	43
Fermented drink Neera (coconut)	<i>L. brevis</i>	55
Kefir (acidic-alcoholic fermented milk product)	<i>L. kefirianofaciens</i> , <i>Lactobacillus acidophilus</i> , <i>L. delbrueckii ssp.</i> , <i>L. plantarum</i>	56
Fruits (guava, green apples, corn, oranges)	<i>Lactiplantibacillus plantarum</i> , <i>Leuconostoc pseudomesenteroides</i> , <i>Weissella confusa</i> , <i>Leuconostoc mesenteroides</i>	57
Faeces (Yak and Cattle)	<i>B. velezensis</i> , <i>L. plantarum</i>	37

causes dysbiosis, alleviating human diseases, such as an observed increased fat diet in individuals suffering from type II diabetes, which has been associated with increased concentrations of lipopolysaccharides and decreased numbers of *Bifidobacterium* in the gut causing metabolic endotoxemia⁴²⁻⁴³. These microbes secrete several metabolites by metabolizing the undigested substrate of the human gut such as SCFAs, including acetic acid, butyric acid, propionic acid and proteins. SCFAs play an essential role in regulating the pH, and increasing the absorption of ions such as magnesium, iron and calcium, and aid in the metabolism of glucose and proteins in the liver. They also help in maintaining gut integrity, via mucus production as well as the function in immunomodulation, appetite regulation and overall homeostasis⁴⁴⁻⁴⁵. Butyrate, mainly produced by *Bacteroidetes* and *Firmicutes*, regulates epithelial cell proliferation, differentiation, anti-inflammatory responses, apoptotic pathways in addition to exerting its effect on gut T-regulatory cells (Treg cells). Probiotics secrete glycoproteins, which exert its effects on gut physiology, and may be involved in immunomodulation of the host tissue, surface recognition and molecular cross-talking where components of one signal pathway affects the other; signalling cascades. Probiotic *L. plantarum* has been identified to secrete proteins, such as PL23; known as muramidase and PL24; known as GAPDH. Muramidase surface proteins cause hydrolysis of the peptidoglycan layer of bacteria and are involved in cell wall turnover, cell separation and division. GAPDH is a cytoplasmic protein found to bind to human colonic mucin and blood antigens⁴⁶. *L. rhamnosus* GG (LGG) secretes proteins p40 and p75, which promote intestinal epithelial cell homeostasis via pathways and involving 3 main mechanisms. These soluble proteins transactivate the epidermal growth factor receptor, which upregulates expression of a proliferation-inducing ligand (APRIL), that in turn promotes the production of Ig-A immunoglobulin and impairs the cytokine induced apoptosis in small intestinal epithelial cells of mouse

models. Intestinal bacteria trigger T-cell dependent B-cell class switching for IgA production via expressing signalling cytokines, such as APRIL⁴⁷. The activation of EGFR by p40 ameliorated apoptosis of colon intestinal cells and chronic inflammation in oxazolone-induced colitis⁴⁸. P70 and p40 can also stimulate the epithelial cells to produce heat stress shock proteins Hsp72 and Hsp25 that protects the tight junctions, and activate the signalling pathway Akt-pathway in phosphatidylinositol 3-kinase-dependent manner, which increases the proliferation and survival of the guts epithelial lining⁴⁸⁻⁴⁹. Fermented soya milk containing probiotic *L. rhamnosus* showed hypotensive properties, higher antioxidative properties and blood pressure-lowering effects potentially through the production of metabolites, such as aglycone isoflavones⁵⁰. Bacteria also produces antimicrobial proteins; ribosomally synthesized: called bacteriocins, which have a wide range of applications, such as anti-viral, and anti-microbial, and act synergistically with food-grade substances⁵¹. Certain probiotic strains like the *Lactobacillus* could inhibit enterohemorrhagic *E. coli* strains in mice by producing bacteriocins⁴⁵.

Dysbiosis in the elderly and diseased population

Aging is associated with various changes in the guts microbiome composition. Aging is often accompanied by dysbiosis, resulting in a significant shift in the ratio of bacterial colonial phyla, or influencing the colonization of new bacterial groups that often leads to imbalance promoting for the occurrence of various diseases. An overrepresentation of pathobionts, such as Enterobacteriaceae, and a loss in the beneficial microflora can also characterize dysbiosis. The elderly have been found to have lower populations of *Firmicutes*, majorly *Clostridium* IXVa, *Faecalibacterium prausnitzii* and *Actinobacteria*⁵⁸. Dysbiosis is associated with aberrations of the gut integrity and enhanced effect of pro-inflammatory cytokines, all such factors eventually can be potent causes of pathogenesis and progress of various other metabolic diseases, which are seen to be more prevalent

in old individuals, such as insulin resistance, adiposity, cardio-vascular diseases, atherosclerosis⁵⁹.

A pro-inflammatory state caused because of the expansion of leakage of microbial contents leads to an inflammatory condition that impairs the nervous system⁶⁰. Due to the reduction of beneficial commensals, the expression of different metabolites, like the lipid metabolites and SCFA, such as acetate, butyrate, and propionate, get reduced. Acetate, after absorption, increases cholesterol synthesis; while propionate is known to inhibit cholesterol synthesis after being metabolized by the liver. These SCFA together help eradicate pathogenic bacteria by lowering the pH of the gut⁶¹. The loss of this metabolic activity collectively leads to dysbiosis in adults. Gram-negative bacteria, such as *Enterobacteriaceae*, produce lipopolysaccharides that act as bacterial endotoxins released in the gut, leading to endotoxemia⁶². In a study on rat models, probiotics *Bifidobacterium breve* and *Lactobacillus fermentum* prevented dysbiosis and reduced endotoxemia mainly by acting on the Tregs⁶³. The SCFA, besides providing energy within the colon, also regulates the signaling pathway and plays a part in the regulation of glucose/insulin regulation through their interaction with G-protein receptors, such as GPR41 and GPR43. Probiotics also act as histone deacetylase inhibitors and indirectly act on gene regulation inducing anti-inflammatory responses. The accumulation of pro-inflammatory commensals also leads to age-related morbidities, systemic inflammation and may cause premature death⁶⁴. Decreased microbial diversity due to aging also leads to a decrease in the secretion of major cofactors and the functioning of DNA repair genes, which caused enhanced muscle wasting in animal mice models⁶⁴. The concept that probiotics can have beneficial effects on the health and immunity of elderly individuals has been validated by various previous studies.

A study on 161 elderly subjects over the age of 65 years was carried out to correlate the functional leakage of gut microbiome and the associated health risk

through fecal microbiome screening. The results showed that *Bacteroides* dominated 68% of the individuals gut; averaging 57% across the subjects; whereas, Phylum *Firmicutes* had an average of 40% abundance. There also occurred varied proportions of disease-associated genera of bacteria including: *Proteobacteria*, *Actinobacteria*, and *Faecalibacteria*, which was observed in different individuals. The effects of antibiotics on microbial composition were also observed as a significant reason for causing an increase in Bacteroidetes: Firmicutes ratio and a relative decrease in *Firmicutes*. The data showed lower diversity of microbiota in elderly individuals compared to young adults⁶⁵. Eloë-Fadrosch et al., investigated as to whether *Lactobacillus rhamnosus* (LGG) could alter the transcriptional response of gut microbiota. The trial was conducted on 12 individuals that were administered 10¹⁰ CFU twice a day of LGG. Metagenomic analysis and 16S rRNA profiling of the gut gene content revealed that *Bifidobacterium* and major butyrate-producing *Roseburia* and *Eubacterium* expression increased through the consumption of probiotic LGG, which suggested an increased interaction between the microbiota and the host epithelium⁶⁶. An animal model study conducted on Kyoto rats (WKY) and hypertensive rats (SHR), to study the effect of probiotics *Lactobacillus fermentum* (LC40) and *Bifidobacterium breve* (BFM), showed that the rats treated with probiotics prevented dysbiosis through lowering the *Firmicutes/Bacteroidetes* ratio and increased butyrate-producing bacteria; resulting in a lower incidence of endotoxemia⁶⁷.

Fecal microbiota transplantation (FMT) therapy has recently gained much interest in re-establishing eubiosis in patients suffering from gut-microbial imbalances, aiming to enhance the patient's health. FMT introduces fecal suspension from a healthy donor to a diseased individual's GI to normalize the composition and benefit the patient. FMT is a successful therapy for treating *Clostridium difficile* infection and other gastrointestinal diseases, such as inflammatory bowel disease⁶⁸. Additionally, synbiotics

have also been used in probiotic therapy as of late. This is a combination of two or more probiotics, or bacterial strains that improve the growth of beneficial commensals and also stimulate the proliferation of native bacterial strains in the gut. The synbiotics exert their effect by modulating the bacterial metabolite secretions and exhibiting anticarcinogenic effects by inactivating cancerogenic substances⁶⁹. Based on the data available, further analysis is required to potentially use probiotics as a therapy to restore the dysbiosis in the gut and alleviate the symptoms caused because of it.


Probiotics and nutritional therapy for older population

The interplay of gut microbiome in aging

The age related decline, termed as: immunosenescence, is majorly attributed to the significant shift in the composition of the gut microbiome and the deterioration of its functions. Disability, mortality, and age-related disorders that come with aging are accomplices to the imbalance in the gut microbiome structure and dysbiosis. The continuously changing abode of the gut, makes the microbiome able to

respond dynamically by changing its bacterial structural build-up and its functions⁷⁰.

It was found that elderly individuals contain different gut microbiome associated with several factors, such as lifestyle changes, altered morphology, slower physiological processes, a weakened immune system, deterioration of functioning of various organs and glands, medications and hospitalization. The intestinal microbiota is crucial in expanding and developing gut mucosal and systemic immune systems. A reduction in microbiota diversity is speculated to have an increase in age-related frailty. Studies on the aging intestine of *Drosophila* suggested a stage of increased immune dysfunction, inflammatory condition, commensal dysbiosis and over-proliferation of intestinal stem cells⁷¹. Maintaining a state of equilibrium in the gut microbiome can help limit such response and improve overall immune health. A recent study on the mice model showed that in aged mice, imbalanced gut conditions lead to increased gut permeability. This further leads to leakage of microbial metabolites and causes systemic inflammation.



SCFA=short-chain fatty acid

Figure 1 Dysbiosis vs. Normal Gut Flora: a schematic representation of gut conditions

Dysbiosis associated with aging disrupts the balance between pro-inflammatory and anti-inflammatory molecules, leading to a state of inflammation described as chronic and a non-resolving inflammatory state. This increases the exposure of cell inflammatory mediators to tumor necrosis factor- α (TNF α), interleukins and C-reactive proteins, which are common in aged individuals⁷⁰. These inflammatory mediators cause age-related morbidities, such as insulin resistance, cardiovascular diseases and a decline in the activity of CNS and mortality.

Several studies and trials have shown that *Lactobacillus* spp. and *Bifidobacterium* spp. can control oral microorganisms; including cariogenic *streptococci*. Several mechanisms of action have been suggested; for example: allowing probiotics to interact directly with dental plaque colonies by disrupting the plaque biofilm through competitive binding to host tissues and for nutrients. Lactic acid bacteria produce antimicrobial compounds, such as hydrogen peroxide, bacteriocins, organic acids and anti-adhesion molecules, which help in inhibition of the growth of other oral bacteria. Indirect actions of probiotics in the oral cavity include modulation of the immune system via interaction with immunocompetent cells. This enhances mucin production, up-regulating host defence peptides and promoting wound healing and angiogenesis⁷²⁻⁷³. *Lactobacillus rhamnosus* GG was found to alter the microbial balance in the oral cavity and reduce the overgrowth of pathogens, such as *Candida*, which are found to increase as aging due to impaired immunity. In the mice model experiment, *Lactobacilli* was seen to shorten the duration of *Candida* colonization in the oral cavity by inducing the production of IL-4 and IFN- γ in lymph nodes and nitric oxide saliva⁷⁴⁻⁷⁶.

Immunosenescence also contributes to altered bacterial composition leading to bowel diseases as a result of increased intestinal permeability, as there is increased interleukin-6 secretion and elevated claudin-2 levels⁷⁷. Microbiota also affects the gut's immune-modulatory status,

which is associated with increased TNF, IL-6 and IL-8⁷⁸. Due to reduced microbial diversity in elderly individuals there is also a reduction in microbiota-related metabolites, such as SCFAs such as butyrate, and propionate, which may be associated with age-related irregular bowel transit, reduced appetite, cognitive decline, hypertension, arthritis, sarcopenia and so forth. This may also increase the susceptibility to Inflammatory bowel disease (IBD) as well as Crohn's disease, due to an increase in pathobionts into the intestinal mucosa. The decline in bacterial metabolites can affect the neuro-immuno axis activation by affecting processes, such as gluconeogenesis, which may also be linked with neurodegenerative diseases⁵⁹.

Immuno-modulatory effect of gut microbiome in elderly population

Aging is accompanied by immunological deterioration, which especially affects the immune cells and the cell-mediated immunity due to a decrease in proliferation of the lymphocyte and interleukin-2 production. During aging there is an increased accumulation of reactive oxygen species and an increase in the proinflammatory cytokines⁷⁹. In an experiment conducted by Chiang et al., a group of 50 healthy volunteers, aged 41–81 years old, were given low-fat milk containing 25g/200ml of *B. Lactis*. The study was conducted to understand the immune enhancement by supplementing probiotic *Bifidobacterium lactis* HN019. It was observed that groups treated with *B. Lactis* had significant changes in the polymorphonuclear cells phagocytosis and the NK cell's tumor killing activity. The activity was seen higher in individuals with more exposure to the probiotic bacteria having a longer duration of consumption. The consumption of probiotic Lactic acid bacteria increases the body combat ability against infections, which is particularly more relevant in aging individuals that are more prevalent to infections because of decreased immunity⁸⁰. Lefevre, et al, conducted a study on 100 individuals, aged 60–74

years, to analyse the effect of *Bacillus subtilis* consumption on immunity and resistance to common infectious diseases. The subjects consumed 2×10^9 *B. subtilis* spores per day for 10 days intermittently, with an 18 day break interval, which was then repeated 4 times during the course of the study. The study showed that consumption of probiotics significantly increased the fecal and salivary secretory of IgA antibody concentrations compared to the placebo group. A post-study analysis also showed a decreased frequency of respiratory infections in the probiotic-supplemented group⁸¹.

The bacteria in the gut continuously interact with the intestinal mucosa. Probiotics show various initiating interactions with the intestinal enterocytes that produce immunomodulatory molecules, such as the production of chemokines and cytokines. It was observed that certain bacterial strains, like *Lactobacillus sakei*, induced interleukine production, such as IL-1 β , IL-8 and tumor necrosis factor- α . In contrast, another strain *L. johnsonii* stimulates TNF- β in an in-vitro experiment on the expression of anti-inflammatory molecules in a strain-dependent manner⁸². Another study by Galdeano and Perdigon proved that probiotics, or their metabolic products, persist in close association with gut-associated lymphoid tissue. They carried out fluorescence labeling of bacteria *Lactobacilli* and traced its presence in Peyer's patches of mice, which were made to feed on these tagged bacteria. Fluorescence was detected in the immune cells of Peyer's patches, crypt and lymph nodes in the small intestine⁸³. The presence of these bacteria or their metabolic product persistence was time-relative and specific to initiate a specific response. In another clinical trial Akatsu et al., the effect of probiotic *Bifidobacterium longum* BB536 on elderly patients, fed by tube feeding, was assessed for its impact on the determination of immune function and intestinal microbiota composition. The study was conducted for 12 weeks on 45 elderly patients (mean age 81.7 years), who were supplemented with BB536 powder containing 5×10^{10}

CFU/2 g daily twice for 12 weeks, while the placebo group were administered 2 g of dextrin powder. After 4 weeks of the administration period, all the patients were given an influenza vaccination. The results showed that the total *B. longum* number increased significantly in the probiotic group compared to the placebo group, and the activity of the natural killer cells also decreased significantly in the placebo group, but not in the probiotic-administered group. The data indicated that long-term ingestion of *Bifidobacterium longum* BB536 could have a beneficial immune modulation effect in elderly patients⁸⁴.

Probiotics also exerts their effects on natural killer (NK) cells; experimentally, *L. rhamnosus* and *B. Lactis* were seen to increase the cytotoxic potential of NK cells effectively. This ability decreased after the probiotic consumption was stopped. It was observed that a combination of *L. casei* coupled with dextran enhanced the activity of NK cells. This property of probiotics is linked to the production of IL-12 from the intestinal epithelial cells; an essential cytokine for NK cell activity⁸⁵. In a randomized placebo-controlled single-blind crossover study conducted by⁸⁶ 30 healthy older volunteers, aged 55–74 years, were assessed for the immunomodulatory effect of *Lactobacillus casei* Shirota. The subjects were given 2x65 ml of Yakult light drink containing 6.5×10^6 CFU/bottle. The volunteers showed increased activity of NK cells during the probiotic drink intervention period, while their phagocytosis, mucosal immunoglobulin A production also was seen to be improved. Many other physiological model experiments demonstrated that probiotic colonised guts increased the secretions of various Interleukins, natural killer cells and other immune cells through its immune-modulatory effects. Probiotics can also stimulate IgA production by B-cells and help in humoral immunity by binding to the antigens and limiting infections to the gut epithelium⁸⁷ (Table 2).

Probiotics are also involved in maintaining bone health. Osteoporosis has been linked to inflammatory

bowel diseases and the result of intestinal inflammation. In an experiment treating healthy mice with *Lactobacillus reuteri* it was seen to enhance intestinal TNF α levels and enhance bone density. Additionally, it was seen to increase trabecular bone parameters, such as mineral density, bone volume fraction and trabecular thickness in the distal femur metaphyseal region and lumbar vertebrae. However, no such effects were seen in experiments in female mice⁸⁸. In animal models, probiotics have been shown to prevent

bone loss by modulating bone resorption formation by osteoclasts and osteoblast cells. They are found to interfere with the concentration of 25-hydroxyvitamin D and in calcium intake, helping to decrease bone loss in elderly and post-menopausal women⁸⁹. Probiotic *Lactobacillus reuteri* on oral supplementation, with bile salt hydrolase, actively increases circulating 25- hydroxyvitamin D levels in hypercholesterolemic adult men and women between aged 20–75 years old⁹⁰.

Table 2 Probiotics for elderly: dosage and disease response

Probiotics	Dosage	Effects	Source
Biotics <i>Bifidobacterium breve</i> and <i>Lactobacillus fermentum</i>	–	Reduction in endotoxemia and regulate T-cells	79
<i>Lactobacillus rhamnosus</i> GG	10 ¹⁰ CFU twice a day	Alters transcriptional responses in gut	82
<i>Bifidobacterium Lactis</i>	25g/200 ml	Increased activity of Natural killer cells and phagocytosis	80
<i>Lactobacillus casei</i> Shirota	2x65 ml of yakult light drink containing 6.5x10 ⁶ CFU/bottle	Increased activity of natural killer cells, enhanced phagocytosis and mucosal immunoglobulin A production	81
<i>Bifidobacterium longum</i> BB536	5x10 ¹⁰ CFU/2 g daily twice for 12 weeks	Enhanced natural killer cell activity, increased number of <i>B. longum</i> micro-flora in gut	84
<i>Bacillus subtilis</i> CU ₁	2x10 ⁹ spores/day	Increased the secretory of IgA antibody, decreased common infections	81
<i>Lactobacillus</i> ; <i>L. plantarum</i> , <i>L. paracasei</i> , <i>L. bulgaricus</i> , <i>L. acidophilus</i> , <i>Bifidobacterium</i> , <i>B. breve</i> , <i>B. longum</i> , <i>B. infantis</i> , and <i>Streptococcus thermophilus</i>	4.9x10 ¹¹ lyophilized bacteria/sachet	Lower incidence of diarrhoea, increased level of serum albumin and prealbumin	95
<i>Bifidobacterium longum</i>	10 ⁹ CFU/day	Higher levels of TNF- α , lower serum IL-10 levels, influences the immune inflammatory response	94
<i>L. johnsonii</i> La1	Fermented milk containing 10 ⁹ CFU for 12 weeks	Improvement in immune response, increase in serum cholinesterase levels and nutritional status, lower level of infection	96
<i>Lactobacillus acidophilus</i> CL1285 [®] and <i>Lactobacillus casei</i> LBC80R [®]	Capsule contained 50x10 ⁹ CFU	Lower incidence of antibiotic- associated diarrhoea	102
<i>A. muciniphila</i>	5x10 ⁸ /0.5 ml–5x10 ⁶ /0.5 ml	Reducing hepatic glycogen levels, resist gluco/lipototoxicity	19
<i>Pediococcus pentoseceus</i> , <i>Leuconostoc mesenteroides</i> , <i>Lactobacillus paracasei</i> and <i>Lactobacillus plantarum</i>	10 ¹⁰ CFU/sachet	Significantly decrease pathogenic bacterial outgrowth, decreases minimal hepatic encephalopathy in cirrhotic individuals	93

CFU=colony forming unit

The use of probiotics for Functional bowel disease in an elderly population

Gastrointestinal microbiota and the probiotics have metabolic activity, which helps convert non-digested carbohydrates into shorter fatty acid chains. Many bowel diseases are linked to the presence and diversity of the gut microbiome. Irritable bowel syndrome is characterized by symptoms, such as abdominal pain associated with disordered defecation or bowel habits. The disease at severe levels may lead patients to undergo a hysterectomy, appendectomy or cystoscopy. IBS is denoted as a biopsychosocial disorder; wherein, the majority of three interacting mechanisms are altered: the psychosocial factors, altered motility, leading to bowel dysfunction and increased sensitivity of the intestine walls⁹¹. Studies have investigated the microbiota associated with the intestine in patients with IBS. Meta-analysis has indicated that probiotics have beneficial effect on abdominal pain and stomach bloating⁹².

Inflammatory bowel disease can be described as: ulcerative colitis with continuous inflammation and sores occurring along the large intestine and Crohn's disease; wherein, the inflammation is discontinuous. This leads to diarrhea, internal bleeding in the rectal and abdominal walls. It has been found that *Faecalibacterium prausnitzii* has anti-inflammatory properties, and is naturally found to be in lesser numbers in individuals suffering from IBD⁹³. Therapeutic use of probiotics has arisen from the findings that the microbiota has a major role in the predisposition of this disease. Different bacterial strain modules affect different intercellular signaling pathways through different pattern recognition receptors. They mediate their actions by manipulating the intestinal mucosal lining as well as the enzymes and secretions they release. Currently, five different probiotic mechanisms are being focussed on for therapeutics of IBD: 1) the probiotics competitively act on the receptors by preventing the microbial pathogens from

acting on them, 2) through their immunomodulatory effect and stimulating the gut-associated lymphoid patches to act on these pathogens, 3) release of antimicrobial factors from the Probiotics, such as lactic and acetic acid, bacteriocins, 4) enhancing the role of the mucosal barrier through probiotics and 5) inducing T-cell apoptosis. Ouwehand et al., conducted a double-blind placebo-controlled trial on 209 elderly individuals to study the influence of *Bifidobacterium* microbiota on the immunity of the elderly, and its association with the level of cytokine regulation. The intervention group (n=56) received an oat-based drink; consisting of 10^9 CFU/day of *Bifidobacterium longum* (*B. longum*) 2C, the placebo group was supplemented with the non-probiotic product, while the control group were given a commercial oat drink. The study showed that *B. longum* was the most detected probiotic in the gut of subjects (94.2 %), followed by *B. adolescentis* (63.5%). The control group had the lowest levels of IL-10 during the course of the study (6 months) compared to the placebo and intervention group. The tumor necrosis factor (TNF- α) was seen at higher levels in the intervention group. The serum IL-10 levels were significantly lower in individuals colonised with *B. longum* (2.5 pg mL^{-1}), and a similar trend was observed in case *B. animalis*. The results indicated that *Bifidobacterium* may influence the inflammatory response in the elderly correlating to the increased serum level of transforming growth factor (TGF- β 1)⁹⁴.

A study was conducted on 243 elderly patients with bowel problems and diarrhea to test the impact of the probiotics on prevention of problems with bowel movement and infection. The patients were assigned into two groups. The study group (n=129) received 4.9×10^{11} viable lyophilized bacteria containing four strains of lactobacillus: *L. plantarum*, *L. paracasei*, *L. bulgaricus*, *L. acidophilus*, *Bifidobacterium*; *B. breve*, *B. longum*, *B. infantis*, and *Streptococcus thermophiles* and the placebo group (n=114). The results showed that the incidence of diarrhea was significantly

lower in the study group compared to the placebo group. The serum albumin, prealbumin and level of protein was also significantly increased in the treatment group among patients aged lower than 80 years of age⁹⁵.

In another study, conducted by Fukushima, et.al., 24 elderly patients (above the age of 70 years) were given probiotics fermented milk to test the effects of probiotic *L. johnsonii* La1 on infection incidence and nutritional status. The subjects in the experimental group were administered fermented milk containing 10^9 CFU and non-probiotic strain *Streptococcus thermophilus* at 10^8 CFU/90 g for 12 weeks. It was observed that the overall immune response improved in addition to the infection duration being reduced after administering fermented milk containing the *L. johnsonii* La1 probiotic. There was also an increase in serum cholinesterase levels, a marker for liver function seen in the probiotic-administered group⁹⁶.

Probiotics in prevention of diarrhoea in an elderly population

Diarrhoea is characterised by loose, watery stools, possibly from frequent bowel movements associated with bacterial infections, viruses in the intestine, malabsorption of food and certain toxins released through food intake. At severe times, it is accompanied by symptoms, such as vomiting, abdominal pain, weight loss, and fatigue. If the condition lasts for more than 2 days it is called: acute diarrhoea. It can be self-treated by replacing the lost fluids and electrolytes through electrolyte replacement drinks or intravenous therapy. Certain probiotics, such as *Lactobacillus GG*, *Saccharomyces boulardii* and a combination of *B. lactis* and *S. thermophilus* have been tested in preventing AAD⁹⁷. A study conducted⁹⁸ on 135 patients (mean age 74 years), having antibiotic unrelated diarrhoea, were treated with probiotic yoghurt drink containing *Lactobacillus casei* (1×10^8 CFU/ml), *S. thermophilus* (1.0×10^8 CFU/ml), and *L. bulgaricus* (1.0×10^7 CFU/ml). the participants drank 97ml

of the drink twice before meals. A significant reduction in the incidence of *C. difficile* was associated with diarrhoea and antibiotic-associated diarrhoea in the probiotic group.

Antibiotic-associated diarrhoea (AAD) is an intestinal complication commonly found in older adults of age 65 years and above, due to antibiotic-lead disturbances causing altered microbiota in older patients⁹⁹⁻¹⁰⁰. Castagliuolo et. al. reviewed that *Saccharomyces boulardii* may have unique properties to secrete a particular protease that hydrolyses Toxin A produced by the *C. difficile*, which is the major pathogen involved in AAD and it induces an anti-inflammatory response by secreting IgA antibodies specific for *C. difficile* toxin in the colon¹⁰¹.

Another study, conducted by Gao et.al on 236 adult patients, for the efficiency of probiotic supplements on AAD, included the samples being divided into 3 groups, all having a differing dosages of probiotics. Group 1 received 1 tablet, group 2 received 2 tablets per day and a third was a placebo group. Each capsule contained 50×10^9 CFU of *Lactobacillus acidophilus* and *Lactobacillus casei*; with the exception of the placebo group. They observed a dosage response relationship; wherein, a higher dose of probiotics resulted in a lower incidence of AAD. The patients treated with the capsules containing the probiotics reported a shorter duration of AAD¹⁰².

Probiotics in hepatic diseases in an elderly population

Hepatic encephalopathy (HE) is characterised by chronic liver disease: cirrhosis, which causes impaired brain functioning and neurological disorders. A broad spectrum of neurological dysfunction can be observed in patients suffering from HE. The pathogenesis of HE is not specific, but mostly multifactorial. The ammonia produced in the body is considered to be a vital factor for the pathogenesis of HE. There is an observed loss of ammonia production and clearance in patients with HE. Several toxin accumulation

and antibiotic therapies are among the other reasons that can possibly cause HE. Probiotic administration can have beneficial effects on the treatment of minimal HE. In action, probiotics can help treating HE by decreasing urease activity, decreasing ammonium absorption and intestinal permeability together, so as to decrease the total ammonia in the blood portal. In normal human beings, ammonia converts to urea, which is excreted by the kidneys; however, in patients with HE there is an excess of urease enzyme activity of the gut microbiome. The target of these therapies is to block this urease enzyme activity. Probiotics can also dissolve toxins and convert them, so as to produce less toxic products, thereby reducing inflammation and oxidative stress¹⁰³.

Ultrastructural changes in the hepatic sinusoidal endothelium and deposition of lipofuscin and multinucleated cells in the hepatic parenchyma generally occur when individuals age. Hepatic malfunctioning can occur due to the bacterial endotoxins released from the gut microflora. Endotoxemia is reconsidered to cause liver damage¹⁰⁴. Endotoxemia occurs when the death of the bacteria release endotoxins into the bloodstream. Probiotics can be administered to increase the number of beneficial bacteria and decrease the toxic effect of endotoxemia in older individuals¹⁰⁵.

A research experiment was conducted to screen for minimal HE and its potential treatment with synbiotics. Patients with cirrhotic liver disease and minimal HE were randomized to receive oral supplementation of symbiotic preparation, containing freeze-dried *Pediococcus pentoseceus*, *Leuconostoc mesenteroides*, *Lactobacillus paracasei* and *Lactobacillus plantarum* (10^{10} CFU per sachet). The patients were divided into 3 groups (aged grouping of 55 years and above) and were administered the supplements for 30 days. The cirrhotic patients with minimal HE significantly decreased the outgrowth of *E.coli* and *staphylococcus spp.* compared to healthy

controls. There was a 50% reversal in minimal HE in patients and a significant reduction in endotoxemia¹⁰⁶. A similar result was observed in a study conducted on intestinal lymphocytes of an experimental mice model with cirrhosis; wherein, the administration of *Bifidobacterium pseudocatenulatum* decreased expression of pro-inflammatory chemokines receptors; like CCR6, which are upregulated in patients with chronic liver diseases¹⁰⁷.

Primary biliary cirrhosis, wherein the bile ducts are destroyed, is a prevalent disease in middle-aged women and individuals over 65 in 30%–40% of cases¹⁰⁸. The Kupffer cells are subset of macrophages present in the liver cells, which act as the primary line of defence against pathogens regulating the liver immune homeostasis. TLR expressed in the liver sense the endotoxins of gut derived pathogens and contribute to macrophage activation. The increased susceptibility to LPS may lead to lipotoxicity and alleviate liver injury⁶⁸. In Zhang et al., they conducted a study experiment on a mice model and showed that *A. muciniphila* can resist gluco/lipotoxicity by reducing hepatic glycogen levels, and could potentially be used as an ideal probiotic¹⁹.

The intestinal microbiota regulates the reactive oxidative species produced in the body. Oxidative stress damages the liver cells causing lipofuscins bodies, which are cross-linked under degradable protein aggregates that accumulate in the liver cells. Lipofuscins caused increased generation of reactive oxidative species and decreased cell survivability¹⁰⁹.

Safety and regulation

The world health organization and food and agriculture organization (FAO) of the United Nations have permitted the acceptable use of certain living organisms or Probiotics that confer potential health benefits to individuals. As stated by FAO, probiotics should be able to not only survive the digestive tract, but also be able to proliferate

and be resistant to gastric juices and intestinal conditions. For the use of probiotics in humans, there should be in-vitro tests that predict the ability of the probiotic to function. The preliminary strain selection of probiotics includes: investigating its functional features and effects on resistance to gastric acidity and bile toxicity, stimulation of the host immune system, adhesion to the gut epithelium and its capability to hydrolyse host metabolites, synthesis of antimicrobial substances and its resistance to antibiotics. Certain bacterial strains may produce extreme antimicrobial resistance, which can be considered potent to the gut as it could disrupt the normal microbial balance. Antibiotic resistance genes have been documented in *Lactobacillus* strains isolated from wine, cheese, poultry, feces and fermented food items. The presence of such genes can be analyzed by conducting whole genome sequencing and standard polymerase chain reaction (PCR) protocols¹¹⁰⁻¹¹¹.

Lactobacilli strains, which are the most commonly administered probiotics, have been recorded to cause bacteremia and liver abscess in 82-year-old women suffering from diabetes mellitus, hypertension and renal disease. However, such cases are rare, and only 7 reported incidences have been found previously¹¹². Probiotic intake has also been linked to many infectious complications. Fungemia and sepsis are found to be the most occurring infectious complications caused by probiotics. Fungemia was reported most frequently associated with *Saccharomyces* and *S. boulardii*; a commonly used probiotic for treating gastroenteritis, which is considered nearly identical to the *S. cerevisiae* strain and can have potential disease-causing abilities¹¹³. *Lactobacilli*, which are rarely pathogenic, have shown a possible case of *L. rhamnosus* bacteremia in a 50-year-old male individual causing infectious endocarditis¹¹⁴. Another case of bacteremia caused by *L. rhamnosus* was also recorded in an adult patient suffering from severe, active ulcerative colitis, while receiving treatment along with a probiotic formulation¹¹⁵.

Generally higher doses for adults of more than

10 billion CFUs daily are associated with higher study outcomes¹¹⁶. However, it is the primary priority of the probiotic manufacturer to ensure the safety standard of probiotic supplements it produces. Probiotics' safe use and dosage are established through documentation, experiments or historical data from previous studies¹¹⁷. The supplier must guarantee a stringent quality of probiotic supplements and contamination-free composition. Failure of such safety may lead to toxic effects and immunological implications⁶¹. A broader comprehension of the probiotic interaction with microbial, genetic and environmental factors within humans is required to address more microbiota associated conditions. Genetically modified probiotics can be used as a supply of epitopes for improving natural immunity and restoring antigen-specific tolerance as well as oral vaccine delivery. The cell surface components can be targeted as a potential strategy to treat inflammatory intestinal disorders using probiotic bacteria. Fecal microbiota transplantation, which is the transfer of intestinal microbiota from faeces of healthy donor to the GI tract of diseased patients, is growing in popularity. It is mostly used to treat diseases caused by pathogenic or conditionally pathogenic microbes in the gut, and there are increasing studies to apply this therapy in diseases, such as Crohn's disease, multiple sclerosis and neurodegenerative diseases, such as Parkinson's and Alzheimer's disease¹¹⁸. Fecal microbiota transfer is also seen to enhance insulin sensitivity in patients with metabolic syndrome; however, future interventions are required to define the vital functionalities of probiotics¹¹⁹.

Conclusion

In the aged population, the interplay of gut plays a crucial role in overall health of an individual. The relationship between aging, microbiome imbalance and the role of probiotics in restoring the well-being of age individuals is of great interest. Aging can cause a disruption in the composition of bacteria, due to immunosenescence leading to dysbiosis, systemic and local inflammation as

well as more age-related morbidities. Probiotics can be isolated from traditional sources, such as milk and dairy related products, fermented products and non-conventional sources, such as fruits, vegetables, and juices.

When administered in appropriate dosages, probiotics have been proven to be beneficial to the elderly population in combating various diseases, such as diarrhea, functional bowel diseases and hepatic diseases through their immunomodulatory effects. Probiotics enhance the activity of immune cells, such as NK cells, increase phagocytosis and stimulate the activity of signaling molecules. Probiotics, such as interleukins. *Lactobacillus plantarum*, *Bifidobacterium longum*, *Lactobacillus acidophilus*, *Bifidobacterium animalis*, *L. acidophilus* and *P. pentosaceus*, are some of the commonly used probiotics having beneficial effects on the host when administered in appropriate dosages. This review gives an insight into the major and recent findings in the use of probiotics in elderly and adult populations. In addition to the potential therapeutic activities of previously identified probiotics that could be more extensively studied and used in future interventions as an alternative to antibiotic therapies or as a supplement to benefit the overall health of a diseased individual.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

- Guidelines for the evaluation of probiotics in food: report of a Joint FAO/WHO Working Group. London, Ontario, Canada: Food and Agriculture Organization of the United Nations and World Health Organization; 2002.
- Williams NT. Probiotics. *Am J Health Syst Pharm* 2010;67:449–58.
- Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. *Int J Environ Res Public Health* 2014;11:4745–67.
- Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. *Adv Nutr* 2019;10:S49–66.
- Angelin J, Kavitha M. Exopolysaccharides from probiotic bacteria and their health potential. *Int J Biol Macromol* 2020;162:853–65.
- Ciszek-Lenda M. Review paper Biological functions of exopolysaccharides from probiotic bacteria. *Cent Eur J Immunol* 2011;36:51–5.
- Conway J, Duggal NA. Ageing of the gut microbiome: potential influences on immunosenescence and inflammaging. *Ageing Res Rev* 2021;68:101323.
- Arshad FA, Mehmood R, Khan S, Rubina M, Hussain S, Khan A, Farooq O. Lactobacilli as probiotics and their isolation from different sources. *Br J Res* 2018;5:1–11.
- Nozari S, Faridvand Y, Etesami A, Ahmad Khan Beiki M, Miresmaeili Mazrakhondi SA, Abdolalizadeh J. Potential anticancer effects of cell wall protein fractions from *Lactobacillus paracasei* on human intestinal Caco-2 cell line. *Lett Appl Microbiol* 2019;69:148–54.
- De la Torre A, Debiton E, Durand D, Chardigny JM, Berdeaux O, Loreau O, et al. Conjugated linoleic acid isomers and their conjugated derivatives inhibit growth of human cancer cell lines. *Anticancer Res* 2005;25:3943–9.
- Blouin JM, Penot G, Collinet M, Nacfer M, Forest C, Laurent-Puig P, et al. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. *Int J Cancer* 2011;128:2591–601.
- O'Mahony D, Murphy S, Boileau T, Park J, O'Brien F, Groeger D, et al. *Bifidobacterium animalis* AHC7 protects against pathogen-induced NF- κ B activation in vivo. *BMC Immunol* 2010;11:63.
- Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. *Diabetes* 2010;59:3049–57.
- Widodo W, Harsita PA, Ari Surya Sukarno, Nurrochmad A. Antidiabetic effect of milk fermented using intestinal probiotics. *Nutr Food Sci* 2019;49:1063–74.
- Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing *Lactobacillus acidophilus* and *Lactobacillus casei* in high fructose fed rats. *Nutrition* 2007;23:62–8.
- Winkler P, Ghadimi D, Schrezenmeier J, Kraehenbuhl JP. Molecular and cellular basis of microflora-host interactions. *J Nutr* 2007;137:756–72.

17. Michail S. The role of probiotics in allergic diseases. *Allergy Asthma Clin Immunol* 2009;5:5.
18. Pathmakanthan S, Li CKF, Cowie J, Hawkey CJ. *Lactobacillus plantarum* 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. *J Gastroenterol Hepatol* 2004;19:166–73.
19. Zhang W, Zhu B, Xu J, Liu Y, Qiu E, Li Z, et al. *Bacteroides fragilis* protects against antibiotic-associated diarrhea in rats by modulating intestinal defenses. *Front Immunol* 2018;9.
20. Regev A, Schiff ER. Liver disease in the elderly. *Gastroenterol Clin North Am* 2001;30:547–63.
21. Warrington JS, Poku JW, von Moltke LL, Shader RI, Harmatz JS, Greenblatt DJ. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. *J Pharmacol Exp Ther* 2000;292:1024–31.
22. Seitz HK, Xu Y, Simanowski UA, Osswald B. Effect of age and gender on in vivo ethanol elimination, hepatic alcohol dehydrogenase activity, and NAD⁺ availability in F344 rats. *Res Exp Med* 1992;192:205–12.
23. Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-Alcoholic Fatty Liver Disease in Older People. *Gerontology* 2009;55:607–13.
24. Fooladi AA, Hosseini HM, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. *Hepat Mon* 2013;13.
25. Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. *Nat Immunol* 2013;14:676–84.
26. Choi SB, Lew LC, Yeo SK, Nair Parvathy S, Liong MT. Probiotics and the BSH-related cholesterol lowering mechanism: a Jekyll and Hyde scenario. *Crit Rev Biotechnol* 2015;35:392–401.
27. Sivamaruthi BS, Fern LA, Rashidah Pg Hj Ismail DSN, Chaiyasut C. The influence of probiotics on bile acids in diseases and aging. *Biomed Pharmacother.* 2020;128:110310.
28. Ahn YT, Kim GB, Lim KS, Baek YJ, Kim HU. Deconjugation of bile salts by *Lactobacillus acidophilus* isolates. *Int Dairy J* 2003;13:303–11.
29. Lye HS, Rusul G, Liong MT. Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol. *J Dairy Sci* 2010;93:1383–92.
30. Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active *Lactobacillus reuteri* NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. *Br J Nutr* 2012;107:1505–13.
31. Tok E, Aslim B. Cholesterol removal by some lactic acid bacteria that can be used as probiotic. *Microbiol Immunol* 2010;54:257–64.
32. Reid G. Safe and efficacious probiotics: what are they? *Trends Microbiol* 2006;14:348–52.
33. Beausoleil M, Fortier N, Guénette S, L'écuyer A, Savoie M, Franco M, et al. Effect of a fermented milk combining *Lactobacillus acidophilus* C1285 and *Lactobacillus casei* in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. *Can J Gastroenterol* 2007;21:732–6.
34. Sanders ME. Probiotics: definition, sources, selection, and uses. *Clin Infect Dis* 2008;46:58–61.
35. Fontana L, Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gil A. Sources, isolation, characterisation and evaluation of probiotics. *Br J Nutr* 2013;109:S35–50.
36. Lyons KE, Ryan CA, Dempsey EM, Ross RP, Stanton C. Breast milk, a source of beneficial microbes and associated benefits for infant health. *Nutrients* 2020;12:1039.
37. Li Y, Jia D, Wang J, Li H, Yin X, Liu J, et al. Probiotics isolated from animals in Northwest China improve the intestinal performance of mice. *Front Vet Sci* 2021;8:750895.
38. Swain MR, Anandharaj M, Ray RC, Parveen Rani R. Fermented fruits and vegetables of Asia: a potential source of probiotics. *Biotechnol Res Int* 2014;2014.
39. Handajani YS, Turana Y, Yogiara Y, Sugiyono SP, Lamadong V, Widjaja NT, et al. Effects of tempeh probiotics on elderly with cognitive impairment. *Front Aging Neurosci* 2022;14:891773.
40. Dobson A, Cotter PD, Ross RP, Hill C. Bacteriocin production: a probiotic trait? *Appl Environ Microbiol* 2012;78:1–6.
41. Hernández-González JC, Martínez-Tapia A, Lazcano-Hernández G, García-Pérez BE, Castrejón-Jiménez NS. Bacteriocins from lactic acid bacteria. A powerful alternative as antimicrobials, probiotics, and immunomodulators in veterinary medicine. *Animals* 2021;11:979.
42. Drewe J, Beglinger C, Fricker G. Effect of ischemia on intestinal permeability of lipopolysaccharides: Lipopolysaccharide absorption. *Eur J Clin Invest* 2001;31:138–44.
43. Gomes AC, Bueno AA, de Souza RGM, Mota JF. Gut microbiota, probiotics and diabetes. *Nutr J* 2014;13:60.
44. Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal

- microbiome. *Nutrients* 2020;12:1107.
45. Gillor O, Etzion A, Riley MA. The dual role of bacteriocins as anti- and probiotics. *Appl Microbiol Biotechnol* 2008;81:591–606.
 46. Sánchez B, Urdaci MC. Extracellular proteins from *Lactobacillus plantarum* BMCM12 prevent adhesion of enteropathogens to mucin. *Curr Microbiol* 2012;64:592–6.
 47. Wang Y, Liu L, Moore DJ, Shen X, Peek RM, Acra SA, et al. An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. *Mucosal Immunol* 2017;10:373–84.
 48. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. *Gastroenterol* 2007;132:562–75.
 49. Liu Q, Yu Z, Tian F, Zhao J, Zhang H, Zhai Q, et al. Surface components and metabolites of probiotics for regulation of intestinal epithelial barrier. *Microb Cell Fact* 2020;19:23.
 50. Wu H, Jiang L, Shum T-F, Chiou J. Elucidation of anti-hypertensive mechanism by a novel *Lactobacillus rhamnosus* AC1 fermented soymilk in the deoxycorticosterone acetate-salt hypertensive rats. *Nutrients* 2022;14:3174.
 51. Chikindas ML, Weeks R, Drider D, Chistyakov VA, Dicks LMT. Functions and emerging applications of bacteriocins. *Curr Opin Biotechnol* 2018;49:23–8.
 52. Syiemlieh I, Morya S. Dairy and non-dairy based probiotics: a review. *Pharma Innov J* 2022;11:2956–64.
 53. Ranadheera CS, Vidanarachchi JK, Rocha RS, Cruz AG, Ajlouni S. Probiotic delivery through fermentation: dairy vs. non-dairy beverages. *Fermentation* 2017;3:67.
 54. Shori AB. The potential applications of probiotics on dairy and non-dairy foods focusing on viability during storage. *Biocatal Agric Biotechnol* 2015;4:423–31.
 55. Somashekaraiah R, Shruthi B, Deepthi BV, Sreenivasa MY. Probiotic properties of lactic acid bacteria isolated from Neera: a naturally fermenting coconut palm nectar. *Front Microbiol* 2019;10:1382.
 56. Prado MR, Blandón LM, Vandenberghe LPS, Rodrigues C, Castro GR, Thomaz-Soccol V, et al. Milk kefir: composition, microbial cultures, biological activities, and related products. *Front Microbiol* 2015;6:1177.
 57. Linares-Morales JR, Cuellar-Nevárez GE, Rivera-Chavira BE, Gutiérrez-Méndez N, Pérez-Vega SB, Nevárez-Moorillón GV. Selection of lactic acid bacteria isolated from fresh fruits and vegetables based on their antimicrobial and enzymatic activities. *Foods* 2020;9:1399.
 58. Salazar N, Valdés-Varela L, González S, Gueimonde M, de los Reyes-Gavilán CG. Nutrition and the gut microbiome in the elderly. *Gut Microbes* 2017;8:82–97.
 59. Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. *J Diabetes Res* 2018;2018:3462092.
 60. Biragyn A, Ferrucci L. Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging. *Lancet Oncol* 2018;19:e295–304.
 61. Kumar R, Sood U, Gupta V, Singh M, Scaria J, Lal R. Recent advancements in the development of modern probiotics for restoring human gut microbiome dysbiosis. *Indian J Microbiol* 2020;60:12–25.
 62. Kumar M, Babaei P, Ji B, Nielsen J. Human gut microbiota and healthy aging: Recent developments and future prospective. *Nutr Healthy Aging* 2016;4:3–16.
 63. Ducatelle R, Eeckhaut V, Haesebrouck F, Van Immerseel F. A review on prebiotics and probiotics for the control of dysbiosis: present status and future perspectives. *Animal* 2015;9:43–8.
 64. Ragonnaud E, Biragyn A. Gut microbiota as the key controllers of “healthy” aging of elderly people. *Immun Ageing* 2021;18:2.
 65. Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci USA* 2011;108:4586–91.
 66. Eloë-Fadrosh EA, Brady A, Crabtree J, Drabek EF, Ma B, Mahurkar A, et al. Functional dynamics of the gut microbiome in elderly people during probiotic consumption. *MBio* 2015;6.
 67. Robles-Vera I, Toral M, de la Visitación N, Sánchez M, Gómez-Guzmán M, Romero M, et al. Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: Role of short-chain fatty acids. *Mol Nutr Food Res* 2020;64.
 68. Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. *Cell Mol Immunol* 2021;18:4–17.
 69. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. *Nutrients* 2017;9:1021.
 70. Bosco N, Noti M. The aging gut microbiome and its impact on host immunity. *Genes Immun* 2021;22:289–303.

71. Li H, Qi Y, Jasper H. Preventing age-related decline of gut compartmentalization limits microbiota dysbiosis and extends lifespan. *Cell Host Microbe* 2016;19:240–53.
72. Meurman JH. Probiotics: do they have a role in oral medicine and dentistry? *Eur J Oral Sci* 2005;113:188–96.
73. Allaker RP, Stephen AS. Use of probiotics and oral health. *Curr Oral Health Rep* 2017;4:309–18.
74. Elahi S, Pang G, Ashman R, Clancy R. Enhanced clearance of *Candida albicans* from the oral cavities of mice following oral administration of *Lactobacillus acidophilus*. *Clin Exp Immunol* 2005;141:29–36.
75. Lockhart SR, Joly S, Vargas K, Swails-Wenger J, Enger L, Soll DR. Natural defenses against *Candida* colonization breakdown in the oral cavities of the elderly. *J Dent Res* 1999;78:857–68.
76. Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, Korpela R. Probiotics reduce the prevalence of oral *Candida* in the elderly—a randomized controlled trial. *J Dent Res* 2007;86:125–30.
77. Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. *Microbiome* 2017;5.
78. Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi JC, Verschoor CP, et al. Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. *Cell Host Microbe* 2017;21:455–66.
79. Nova E, Wärnberg J, Gómez-Martínez S, Díaz LE, Romeo J, Marcos A. Immunomodulatory effects of probiotics in different stages of life. *Br J Nutr* 2007;98:S90–5.
80. Chiang BL, Sheih YH, Wang LH, Liao CK, Gill HS. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (*Bifidobacterium lactis* HN019): optimization and definition of cellular immune responses. *Eur J Clin Nutr* 2000;54:849–55.
81. Lefevre M, Racedo SM, Ripert G, Housez B, Cazaubiel M, Maudet C, et al. Probiotic strain *Bacillus subtilis* CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. *Immun Ageing* 2015;12:24.
82. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. *Gut* 2000;47:79–87.
83. Galdeano CM, Perdígón G. Role of viability of probiotic strains in their persistence in the gut and in mucosal immune stimulation. *J Appl Microbiol* 2004;97:673–81.
84. Akatsu H, Iwabuchi N, Xiao JZ, Matsuyama Z, Kurihara R, Okuda K, et al. Clinical effects of probiotic *Bifidobacterium longum* BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding. *JPEN J Parenter Enteral Nutr* 2013;37:631–40.
85. Takeda K, Suzuki T, Shimada SI, Shida K, Nanno M, Okumura K. Interleukin-12 is involved in the enhancement of human natural killer cell activity by *Lactobacillus casei* Shirota. *Clin Exp Immunol* 2006;146:109–15.
86. Dong H, Rowland I, Thomas LV, Yaqoob P. Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirota in healthy older volunteers. *Eur J Nutr* 2013;52:1853–63.
87. Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. Immunomodulatory effects of probiotics in the intestinal tract. *Curr Issues Mol Biol* 2008;10:37–54.
88. McCabe LR, Irwin R, Schaefer L, Britton RA. Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. *J Cell Physiol* 2013;228:1793–8.
89. Rizzoli R, Biver E. Are probiotics the new calcium and vitamin D for bone health? *Curr Osteoporos Rep* 2020;18:273–84.
90. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic *L. reuteri* NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. *J Clin Endocrinol Metab* 2013;98:2944–51.
91. Camilleri M. Management of the irritable bowel syndrome. *Gastroenterol* 2001;120:652–68.
92. Whelan K, Quigley EMM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. *Curr Opin Gastroenterol* 2013;29:184–9.
93. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of *Faecalibacterium prausnitzii* in colitis microbiota. *Inflamm Bowel Dis* 2009;15:1183–9.
94. Ouwehand AC, Bergsma N, Parhiala R, Lahtinen S, Gueimonde M, Finne-Soveri H, et al. *Bifidobacterium* microbiota and parameters of immune function in elderly subjects. *FEMS Immunol Med Microbiol* 2008;53:18–25.
95. Zaharoni H, Rimon E, Vardi H, Friger M, Bolotin A, Shahar DR. Probiotics improve bowel movements in hospitalized elderly patients—the PROAGE study. *J Nutr Health Aging* 2011;15:215–20.
96. Fukushima Y, Miyaguchi S, Yamano T, Kaburagi T, Iino H,

- Ushida K, et al. Improvement of nutritional status and incidence of infection in hospitalised, enterally fed elderly by feeding of fermented milk containing probiotic *Lactobacillus johnsonii* La1 (NCC533). *Br J Nutr* 2007;98:969–77.
97. Guarino A, Guandalini S, Lo Vecchio A. Probiotics for prevention and treatment of diarrhea. *J Clin Gastroenterol* 2015;49:S37–45.
 98. Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, et al. Use of probiotic *Lactobacillus* preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. *BMJ* 2007;335:80.
 99. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. *Future Microbiol* 2008;3:563–78.
 100. Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. *Travel Med Infect Dis* 2015;13:128–34.
 101. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. *Saccharomyces boulardii* protease inhibits the effects of *Clostridium difficile* toxins A and B in human colonic mucosa. *Infect Immun* 1999;67:302–7.
 102. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of *Lactobacillus acidophilus* 1285 and *Lactobacillus casei* bc80r for antibiotic-associated diarrhea and *Clostridium difficile*-associated diarrhea prophylaxis in adult patients. *Am J Gastroenterol* 2010;105:1636–41.
 103. Solga SF. Probiotics can treat hepatic encephalopathy. *Med Hypotheses* 2003;61:307–13.
 104. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, et al. Gut microbiota and probiotics in chronic liver diseases. *Dig Liver Dis* 2011;43:431–8.
 105. Chen C, Li L, Wu Z, Chen H, Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. *J Infect* 2007;54:98–102.
 106. aka Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. *Hepatology* 2004;39:1441–9.
 107. Moratalla A, Gómez-Hurtado I, Moya-Pérez Á, Zapater P, Peiró G, González-Navajas JM, et al. *Bifidobacterium pseudocatenulatum* CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis. *Eur J Nutr* 2016;55:197–206.
 108. Regev A, Schiff ER. Liver disease in the elderly. *Gastroenterol Clin North Am* 2001;30:547–63.
 109. Kim H, Kisseleva T, Brenner DA. Aging and liver disease. *Curr Opin Gastroenterol* 2015;31:184.
 110. Thakur N, Rokana N, Panwar H. Probiotics: Selection criteria, safety and role in health and disease. *J Innov Biol* 2016;3:259–70.
 111. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. *Expert Opin Drug Saf* 2014;13:227–39.
 112. Sherid M, Samo S, Sulaiman S, Husein H, Sifuentes H, Sridhar S. Liver abscess and bacteremia caused by *Lactobacillus*: role of probiotics? case report and review of the literature. *BMC Gastroenterol* 2016;16:138.
 113. Costa RL, Moreira J, Lorenzo A, Lamas CC. Infectious complications following probiotic ingestion: a potentially underestimated problem? a systematic review of reports and case series. *BMC Complement Altern Med* 2018;18:329.
 114. Pasala S, Singer L, Arshad T, Roach K. *Lactobacillus* endocarditis in a healthy patient with probiotic use. *IDCases* 2020;22:e00915.
 115. Meini S, Laureano R, Fani L, Tascini C, Galano A, Antonelli A, Rossolini GM. Breakthrough *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. *Infection* 2015;43:777–81.
 116. Naidu KSB, Adam JK, Govender P. The use of probiotics and safety concerns: a review. *Afr J Microbiol Res* 2012;6:6871–7.
 117. Binda S, Hill C, Johansen E, Obis D, Pot B, Sanders ME, et al. Criteria to qualify microorganisms as “probiotic” in foods and dietary supplements. *Front Microbiol* 2020;11:1662.
 118. Antushevich H. Fecal microbiota transplantation in disease therapy. *Clinica Chimica Acta* 2020;503:90–8.
 119. Nami Y, Haghshenas B, Abdullah N, Barzegari A, Radiah D, Rosli R, Yari Khosroushahi A. Probiotics or antibiotics: future challenges in medicine. *J Med Microbiol* 2015;64:137–46.